Public Health Impact: Screening Programs, Outbreak Readiness, and Community Trust
Blood screening is a public-health linchpin: robust programs protect patients, support safe transfusions, and preserve public confidence in donation drives. When blood centers demonstrate high-sensitivity testing and quick turnaround, donors and clinicians trust the system—encouraging voluntary donation and reducing discard rates. Integrating screening data with national surveillance systems enables rapid detection of emerging threats and targeted donor deferrals. Preparedness plans that include surge-capacity protocols, cross-lab sample sharing, and mobile screening units help maintain supply during crises. Community outreach, transparent reporting of screening performance, and donor education reduce fear and misinformation—critical during outbreaks when donations often fall just when demand rises. Investments in screening not only reduce the risk of transfusion-transmitted infections but also create epidemiological datasets that inform vaccination and prevention strategies. Policymakers increasingly see blood screening as a core public-health investment rather than a discretionary lab cost.
MRFR values: market was USD 2.70 billion (2023), USD 3.40 billion (2024); projected USD 5.60 billion by 2032 (CAGR 10.20%).